Staph Bacteria Use a Pump to Resist the Body's Antimicrobial Peptides — and This Resistance Drives Real Infections | Research

The takeaway

The Staphylococcus aureus Pmt ABC transporter provides first direct evidence that antimicrobial peptide resistance is critical for bacterial infection, defending staph from human AMPs, neutrophil killing, and driving skin infection virulence.

First in vivo proof: AMP resistance drives infection
By showing that the virulence advantage of the Pmt transporter disappeared when antimicrobial peptides were removed from the system, researchers proved that AMP resistance — not just general bacterial fitness — drives S. aureus skin infection.

What the researchers found

The S. aureus Pmt ABC transporter defends bacteria from killing by important human AMPs and from elimination by human neutrophils. Pmt contributes to virulence during skin infection in an AMP-dependent manner — when AMP activity was removed from the experimental system, the virulence advantage of Pmt was eliminated. This provides the first direct in vivo evidence that antimicrobial peptide resistance per se is important during bacterial infection, not just in laboratory conditions.

Why it matters

Antimicrobial peptides are frequently proposed as alternatives to conventional antibiotics, but a major concern has been whether bacteria could evolve resistance that undermines their therapeutic potential. This study shows that AMP resistance mechanisms not only exist but are already clinically important — S. aureus uses them to cause infections. This has implications for both understanding staph pathogenesis and designing AMP-based therapies that can overcome resistance.

How the study worked

Researchers compared wild-type S. aureus to Pmt-deficient mutants for: susceptibility to human AMPs (in vitro killing assays), survival against human neutrophils, and virulence in mouse skin infection models. To prove the effect was specifically AMP-dependent, they performed skin infections under conditions where AMP activity was absent, showing that the virulence advantage of Pmt disappeared — confirming the causal link between AMP resistance and infection outcome.

What this study cannot tell us

The study focused on one resistance mechanism (Pmt transporter) in one bacterial species (S. aureus) during one type of infection (skin). Other AMP resistance mechanisms may operate differently. The mouse skin infection model may not fully represent the complexity of human staph infections. The specific AMPs involved in the Pmt-dependent virulence were not individually identified. Whether Pmt-mediated resistance could be overcome by modified AMPs was not tested.

How to read the evidence

Published in the Journal of Infectious Diseases, this is a well-designed mechanistic study combining in vitro AMP killing assays, neutrophil survival experiments, and in vivo mouse infection models with elegant controls (AMP-dependent virulence demonstration). The evidence for the AMP-resistance → virulence link is convincing within the tested model.

When this study was published

Published in 2018, this landmark study established a principle — AMP resistance contributes to bacterial virulence — that continues to shape how the field approaches AMP drug development and resistance mitigation.

The bigger picture

The antimicrobial peptide field has often argued that bacteria are unlikely to develop significant resistance to AMPs because they've coexisted with these peptides for millions of years. This study challenges that narrative by showing that AMP resistance mechanisms are not only present but actively contribute to infection. This is crucial context for developing AMP-based therapeutics — effective clinical peptides will need to be designed to evade bacterial resistance mechanisms like Pmt.

Questions still open

Can therapeutic AMPs be designed to evade Pmt and similar bacterial efflux pumps?
How widespread are AMP resistance mechanisms across different bacterial pathogens and infection types?
Could Pmt inhibitors be combined with AMPs to restore their killing ability against resistant staph?

Common questions

Can bacteria resist antimicrobial peptides, and does it matter?

Yes on both counts. This study showed that Staphylococcus aureus uses a molecular pump (Pmt) to expel the antimicrobial peptides our immune system produces. When the pump works, staph bacteria survive better against immune cells and cause more severe skin infections. This is important because it means bacteria already have tools to resist the AMPs being developed as new antibiotics.

Does this mean antimicrobial peptides won't work as drugs?

Not necessarily, but it means AMP drug designers need to account for resistance. Just as conventional antibiotics face resistance, AMPs face pumps like Pmt that bacteria use to expel them. Effective AMP therapies may need to be designed to evade these pumps, or combined with pump inhibitors to restore their killing power.

Read the original research

Antimicrobial Peptide Resistance Mechanism Contributes to Staphylococcus aureus Infection.

The Journal of infectious diseases, 217(7), 1153-1159

View on PubMed ↗Publisher’s paper ↗

Citation

Cheung, Gordon Y C; Fisher, Emilie L; McCausland, Joshua W; Choi, Justin; Collins, John W M; Dickey, Seth W; Otto, Michael. (2018). Antimicrobial Peptide Resistance Mechanism Contributes to Staphylococcus aureus Infection.. The Journal of infectious diseases, 217(7), 1153-1159. https://doi.org/10.1093/infdis/jiy024